The efficacy of pioglitazone for renal protection in diabetic kidney disease

There is limited information on the efficacy of pioglitazone in diabetic kidney diseases (DKD). We evaluated whether pioglitazone exerts renal-protective effects in DKD patients. We designed a retrospective cohort study, which included 742 type 2 diabetes mellitus (T2DM) patients with DKD in Taiwan,...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 17; no. 2; p. e0264129
Main Authors Ho, Chao-Chung, Yang, Yi-Sun, Huang, Chien-Ning, Lo, Shih-Chang, Wang, Yu-Hsun, Kornelius, Edy
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 17.02.2022
Public Library of Science (PLoS)
Subjects
Aged
Albuminuria - epidemiology
Albuminuria - prevention & control
Biology and Life Sciences
Cardiovascular disease
Care and treatment
Creatinine
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetic nephropathies
Diabetic Nephropathies - etiology
Diabetic Nephropathies - metabolism
Diabetic Nephropathies - pathology
Diabetic Nephropathies - prevention & control
Diabetic nephropathy
Endocrinology
Enrollments
Epidermal growth factor receptors
Female
Glomerular Filtration Rate
Glucose
Hemodialysis
Hospitals
Humans
Hypertension
Hypoglycemic Agents - therapeutic use
Internal medicine
Kidney - drug effects
Kidney - pathology
Kidney diseases
Kidney transplantation
Kidneys
Male
Medicine
Medicine and Health Sciences
Metabolism
Middle Aged
Patients
Pioglitazone
Pioglitazone - therapeutic use
Retrospective Studies
Taiwan - epidemiology
Transplantation
Taiwan
Online AccessGet full text
ISSN1932-6203
1932-6203
DOI10.1371/journal.pone.0264129

Cover

Abstract There is limited information on the efficacy of pioglitazone in diabetic kidney diseases (DKD). We evaluated whether pioglitazone exerts renal-protective effects in DKD patients. We designed a retrospective cohort study, which included 742 type 2 diabetes mellitus (T2DM) patients with DKD in Taiwan, with eGFR between 30 and 90 ml/min/1.73 m 2 and UACR level 300–5000 mg/g. Patients not meeting the target range for HbA1c (above 7%) were given additional medication with pioglitazone (n = 111) or received standard care (non-pioglitazone group, n = 631). The primary endpoint was the occurrence of composite renal endpoints, which was defined as sustained eGFR<15 ml/min/1.73 m 2 (confirmed by two measurements within 90 days); doubling of serum creatinine (compared to baseline); and the presence of hemodialysis or renal transplantation. The median follow-up duration was two years. At baseline, the mean HbA1C levels in the pioglitazone and non-pioglitazone groups were 8.8% and 8.1%, respectively; mean ages were 64.4 and 66.2 years old, respectively; diabetes durations were 14.3 and 12.3 years, respectively. Baseline eGFR showed no significant difference between the pioglitazone and non-pioglitazone groups (55.8 and 58.8 mL/min/1.73 m 2 , respectively). In terms of gender, 63% of patients were male in the pioglitazone group compared with 57% in the non-pioglitazone group. Pioglitazone use did not reduce the risk of composite renal endpoints in DKD patients (HR: 0.97, 95% CI = 0.53–1.77), including persistent eGFR<15 ml/min/1.73 m 2 (HR = 1.07, 95% CI = 0.46–2.52), doubling of serum creatinine (HR = 0.97, 95% CI = 0.53–1.77), or ESRD (HR = 2.58, 95% CI = 0.29–23.04). The results were not changed after various adjustments. A non-significant albuminuria reduction was also noted after pioglitazone prescription in DKD patients. Further randomized controlled studies are needed to establish the effects of pioglitazone definitively.
AbstractList There is limited information on the efficacy of pioglitazone in diabetic kidney diseases (DKD). We evaluated whether pioglitazone exerts renal-protective effects in DKD patients. We designed a retrospective cohort study, which included 742 type 2 diabetes mellitus (T2DM) patients with DKD in Taiwan, with eGFR between 30 and 90 ml/min/1.73 m2 and UACR level 300-5000 mg/g. Patients not meeting the target range for HbA1c (above 7%) were given additional medication with pioglitazone (n = 111) or received standard care (non-pioglitazone group, n = 631). The primary endpoint was the occurrence of composite renal endpoints, which was defined as sustained eGFR<15 ml/min/1.73 m2 (confirmed by two measurements within 90 days); doubling of serum creatinine (compared to baseline); and the presence of hemodialysis or renal transplantation. The median follow-up duration was two years. At baseline, the mean HbA1C levels in the pioglitazone and non-pioglitazone groups were 8.8% and 8.1%, respectively; mean ages were 64.4 and 66.2 years old, respectively; diabetes durations were 14.3 and 12.3 years, respectively. Baseline eGFR showed no significant difference between the pioglitazone and non-pioglitazone groups (55.8 and 58.8 mL/min/1.73 m2, respectively). In terms of gender, 63% of patients were male in the pioglitazone group compared with 57% in the non-pioglitazone group. Pioglitazone use did not reduce the risk of composite renal endpoints in DKD patients (HR: 0.97, 95% CI = 0.53-1.77), including persistent eGFR<15 ml/min/1.73 m2 (HR = 1.07, 95% CI = 0.46-2.52), doubling of serum creatinine (HR = 0.97, 95% CI = 0.53-1.77), or ESRD (HR = 2.58, 95% CI = 0.29-23.04). The results were not changed after various adjustments. A non-significant albuminuria reduction was also noted after pioglitazone prescription in DKD patients. Further randomized controlled studies are needed to establish the effects of pioglitazone definitively.There is limited information on the efficacy of pioglitazone in diabetic kidney diseases (DKD). We evaluated whether pioglitazone exerts renal-protective effects in DKD patients. We designed a retrospective cohort study, which included 742 type 2 diabetes mellitus (T2DM) patients with DKD in Taiwan, with eGFR between 30 and 90 ml/min/1.73 m2 and UACR level 300-5000 mg/g. Patients not meeting the target range for HbA1c (above 7%) were given additional medication with pioglitazone (n = 111) or received standard care (non-pioglitazone group, n = 631). The primary endpoint was the occurrence of composite renal endpoints, which was defined as sustained eGFR<15 ml/min/1.73 m2 (confirmed by two measurements within 90 days); doubling of serum creatinine (compared to baseline); and the presence of hemodialysis or renal transplantation. The median follow-up duration was two years. At baseline, the mean HbA1C levels in the pioglitazone and non-pioglitazone groups were 8.8% and 8.1%, respectively; mean ages were 64.4 and 66.2 years old, respectively; diabetes durations were 14.3 and 12.3 years, respectively. Baseline eGFR showed no significant difference between the pioglitazone and non-pioglitazone groups (55.8 and 58.8 mL/min/1.73 m2, respectively). In terms of gender, 63% of patients were male in the pioglitazone group compared with 57% in the non-pioglitazone group. Pioglitazone use did not reduce the risk of composite renal endpoints in DKD patients (HR: 0.97, 95% CI = 0.53-1.77), including persistent eGFR<15 ml/min/1.73 m2 (HR = 1.07, 95% CI = 0.46-2.52), doubling of serum creatinine (HR = 0.97, 95% CI = 0.53-1.77), or ESRD (HR = 2.58, 95% CI = 0.29-23.04). The results were not changed after various adjustments. A non-significant albuminuria reduction was also noted after pioglitazone prescription in DKD patients. Further randomized controlled studies are needed to establish the effects of pioglitazone definitively.
There is limited information on the efficacy of pioglitazone in diabetic kidney diseases (DKD). We evaluated whether pioglitazone exerts renal-protective effects in DKD patients. We designed a retrospective cohort study, which included 742 type 2 diabetes mellitus (T2DM) patients with DKD in Taiwan, with eGFR between 30 and 90 ml/min/1.73 m 2 and UACR level 300–5000 mg/g. Patients not meeting the target range for HbA1c (above 7%) were given additional medication with pioglitazone (n = 111) or received standard care (non-pioglitazone group, n = 631). The primary endpoint was the occurrence of composite renal endpoints, which was defined as sustained eGFR<15 ml/min/1.73 m 2 (confirmed by two measurements within 90 days); doubling of serum creatinine (compared to baseline); and the presence of hemodialysis or renal transplantation. The median follow-up duration was two years. At baseline, the mean HbA1C levels in the pioglitazone and non-pioglitazone groups were 8.8% and 8.1%, respectively; mean ages were 64.4 and 66.2 years old, respectively; diabetes durations were 14.3 and 12.3 years, respectively. Baseline eGFR showed no significant difference between the pioglitazone and non-pioglitazone groups (55.8 and 58.8 mL/min/1.73 m 2 , respectively). In terms of gender, 63% of patients were male in the pioglitazone group compared with 57% in the non-pioglitazone group. Pioglitazone use did not reduce the risk of composite renal endpoints in DKD patients (HR: 0.97, 95% CI = 0.53–1.77), including persistent eGFR<15 ml/min/1.73 m 2 (HR = 1.07, 95% CI = 0.46–2.52), doubling of serum creatinine (HR = 0.97, 95% CI = 0.53–1.77), or ESRD (HR = 2.58, 95% CI = 0.29–23.04). The results were not changed after various adjustments. A non-significant albuminuria reduction was also noted after pioglitazone prescription in DKD patients. Further randomized controlled studies are needed to establish the effects of pioglitazone definitively.
There is limited information on the efficacy of pioglitazone in diabetic kidney diseases (DKD). We evaluated whether pioglitazone exerts renal-protective effects in DKD patients. We designed a retrospective cohort study, which included 742 type 2 diabetes mellitus (T2DM) patients with DKD in Taiwan, with eGFR between 30 and 90 ml/min/1.73 m2 and UACR level 300–5000 mg/g. Patients not meeting the target range for HbA1c (above 7%) were given additional medication with pioglitazone (n = 111) or received standard care (non-pioglitazone group, n = 631). The primary endpoint was the occurrence of composite renal endpoints, which was defined as sustained eGFR<15 ml/min/1.73 m2 (confirmed by two measurements within 90 days); doubling of serum creatinine (compared to baseline); and the presence of hemodialysis or renal transplantation. The median follow-up duration was two years. At baseline, the mean HbA1C levels in the pioglitazone and non-pioglitazone groups were 8.8% and 8.1%, respectively; mean ages were 64.4 and 66.2 years old, respectively; diabetes durations were 14.3 and 12.3 years, respectively. Baseline eGFR showed no significant difference between the pioglitazone and non-pioglitazone groups (55.8 and 58.8 mL/min/1.73 m2, respectively). In terms of gender, 63% of patients were male in the pioglitazone group compared with 57% in the non-pioglitazone group. Pioglitazone use did not reduce the risk of composite renal endpoints in DKD patients (HR: 0.97, 95% CI = 0.53–1.77), including persistent eGFR<15 ml/min/1.73 m2 (HR = 1.07, 95% CI = 0.46–2.52), doubling of serum creatinine (HR = 0.97, 95% CI = 0.53–1.77), or ESRD (HR = 2.58, 95% CI = 0.29–23.04). The results were not changed after various adjustments. A non-significant albuminuria reduction was also noted after pioglitazone prescription in DKD patients. Further randomized controlled studies are needed to establish the effects of pioglitazone definitively.
There is limited information on the efficacy of pioglitazone in diabetic kidney diseases (DKD). We evaluated whether pioglitazone exerts renal-protective effects in DKD patients. We designed a retrospective cohort study, which included 742 type 2 diabetes mellitus (T2DM) patients with DKD in Taiwan, with eGFR between 30 and 90 ml/min/1.73 m.sup.2 and UACR level 300-5000 mg/g. Patients not meeting the target range for HbA1c (above 7%) were given additional medication with pioglitazone (n = 111) or received standard care (non-pioglitazone group, n = 631). The primary endpoint was the occurrence of composite renal endpoints, which was defined as sustained eGFR<15 ml/min/1.73 m.sup.2 (confirmed by two measurements within 90 days); doubling of serum creatinine (compared to baseline); and the presence of hemodialysis or renal transplantation. The median follow-up duration was two years. At baseline, the mean HbA1C levels in the pioglitazone and non-pioglitazone groups were 8.8% and 8.1%, respectively; mean ages were 64.4 and 66.2 years old, respectively; diabetes durations were 14.3 and 12.3 years, respectively. Baseline eGFR showed no significant difference between the pioglitazone and non-pioglitazone groups (55.8 and 58.8 mL/min/1.73 m.sup.2, respectively). In terms of gender, 63% of patients were male in the pioglitazone group compared with 57% in the non-pioglitazone group. Pioglitazone use did not reduce the risk of composite renal endpoints in DKD patients (HR: 0.97, 95% CI = 0.53-1.77), including persistent eGFR<15 ml/min/1.73 m.sup.2 (HR = 1.07, 95% CI = 0.46-2.52), doubling of serum creatinine (HR = 0.97, 95% CI = 0.53-1.77), or ESRD (HR = 2.58, 95% CI = 0.29-23.04). The results were not changed after various adjustments. A non-significant albuminuria reduction was also noted after pioglitazone prescription in DKD patients. Further randomized controlled studies are needed to establish the effects of pioglitazone definitively.
Audience Academic
Author Wang, Yu-Hsun
Lo, Shih-Chang
Huang, Chien-Ning
Yang, Yi-Sun
Kornelius, Edy
Ho, Chao-Chung
AuthorAffiliation 2 Department of Internal Medicine, Division of Endocrinology and Metabolism, Chung Shan Medical University Hospital, Taichung City, Taiwan
1 School of Medicine of Chung Shan Medical University, Taichung City, Taiwan
3 Institute of Medicine of Chung Shan Medical University, Taichung City, Taiwan
4 Department of Medical Research, Chung Shan Medical University Hospital, Taichung City, Taiwan
University of Colorado Denver School of Medicine, UNITED STATES
AuthorAffiliation_xml – name: 1 School of Medicine of Chung Shan Medical University, Taichung City, Taiwan
– name: 3 Institute of Medicine of Chung Shan Medical University, Taichung City, Taiwan
– name: 2 Department of Internal Medicine, Division of Endocrinology and Metabolism, Chung Shan Medical University Hospital, Taichung City, Taiwan
– name: University of Colorado Denver School of Medicine, UNITED STATES
– name: 4 Department of Medical Research, Chung Shan Medical University Hospital, Taichung City, Taiwan
Author_xml – sequence: 1
  givenname: Chao-Chung
  surname: Ho
  fullname: Ho, Chao-Chung
– sequence: 2
  givenname: Yi-Sun
  surname: Yang
  fullname: Yang, Yi-Sun
– sequence: 3
  givenname: Chien-Ning
  surname: Huang
  fullname: Huang, Chien-Ning
– sequence: 4
  givenname: Shih-Chang
  surname: Lo
  fullname: Lo, Shih-Chang
– sequence: 5
  givenname: Yu-Hsun
  surname: Wang
  fullname: Wang, Yu-Hsun
– sequence: 6
  givenname: Edy
  orcidid: 0000-0002-9342-5467
  surname: Kornelius
  fullname: Kornelius, Edy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35176115$$D View this record in MEDLINE/PubMed
BookMark eNqNk22L1DAQx4uceA_6DUQLguiLXdMkTRNfCMfhw8LCgZ6-DWk62c2ZbdakFddPb-r2ju1xiLTQdvqb_3T-nTnNjlrfQpY9LdC8IFXx5tr3oVVuvk3hOcKMFlg8yE4KQfCMYUSODu6Ps9MYrxEqCWfsUXZMyqJiRVGeZMurNeRgjNVK73Jv8q31K2c79TvJ5saHPECqkm-D70B31re5bfPGqho6q_Pvtmlhl54jqAiPs4dGuQhPxutZ9vXD-6uLT7Pl5cfFxflyppnA3QwrXhlTVwIrjBCuSdkQxk3FEAVMlaCAOKqamnItGsQ4N6VRFRjBsTaaaHKWPd_rbp2PcjQiSsyw4IgLihOx2BONV9dyG-xGhZ30ysq_AR9WUoXUgANJTFk0ioJqakNNUwtcIUo1pSadWFRJ691Yra830Ghou6DcRHT6prVrufI_JeclKdkg8GoUCP5HD7GTGxs1OKda8P3w3QQJXPAKJfTFHfT-7kZqpVIDtjU-1dWDqDxngiJWlkIkan4PlY4GNlan32tsik8SXk8SEtPBr26l-hjl4svn_2cvv03ZlwfsGpTr1tG7fpimOAWfHTp9a_HNuCaA7gEdfIwBzC1SIDlsxY1dctgKOW5FSnt7J02nCR_KJ0es-3fyH4YiEoA
CitedBy_id crossref_primary_10_1021_acs_joc_2c00991
crossref_primary_10_1111_exd_15065
crossref_primary_10_3892_etm_2024_12681
crossref_primary_10_3390_antiox13040455
crossref_primary_10_1007_s10557_024_07588_8
crossref_primary_10_22141_2224_0721_19_1_2023_1243
crossref_primary_10_3390_biomedicines11102828
crossref_primary_10_3390_ijms241512378
crossref_primary_10_3389_fphar_2024_1379821
Cites_doi 10.3390/ijms19072063
10.1111/dom.12652
10.1371/journal.pone.0129922
10.1016/j.amjmed.2015.03.025
10.1001/archinternmed.2010.207
10.1371/journal.pone.0170874
10.1155/2008/183108
10.2337/dc11-0175
10.1210/clinem/dgz252
10.1161/CIRCULATIONAHA.117.030458
10.1371/journal.pone.0079815
10.1053/j.ajkd.2020.08.003
10.4158/EP-2020-0143
10.1056/NEJMoa1603827
10.1155/2007/62641
10.2337/dc19-S006
10.3390/cells8070749
10.1056/NEJMoa0802743
10.1016/S0140-6736(05)67528-9
10.1016/S0140-6736(10)60576-4
10.1016/S0140-6736(06)69420-8
10.1001/archinte.164.19.2097
10.1056/NEJMoa1811744
10.1056/NEJMoa1506930
10.1056/NEJMoa2024816
10.1089/ars.2016.6664
10.1016/j.biopha.2019.109346
10.2337/diabetes.49.6.1022
10.1053/ajkd.2000.16225
10.1007/s00592-017-0983-0
10.2337/db05-1285
10.1093/ndt/gfn157
10.1016/j.diabres.2019.107843
10.1111/j.1463-1326.2008.00892.x
10.1016/j.pop.2020.08.004
10.1053/j.ajkd.2009.11.013
ContentType Journal Article
Copyright COPYRIGHT 2022 Public Library of Science
2022 Ho et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022 Ho et al 2022 Ho et al
Copyright_xml – notice: COPYRIGHT 2022 Public Library of Science
– notice: 2022 Ho et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022 Ho et al 2022 Ho et al
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
IOV
ISR
3V.
7QG
7QL
7QO
7RV
7SN
7SS
7T5
7TG
7TM
7U9
7X2
7X7
7XB
88E
8AO
8C1
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABJCF
ABUWG
AEUYN
AFKRA
ARAPS
ATCPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
D1I
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
KB.
KB0
KL.
L6V
LK8
M0K
M0S
M1P
M7N
M7P
M7S
NAPCQ
P5Z
P62
P64
PATMY
PDBOC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PTHSS
PYCSY
RC3
7X8
5PM
DOA
DOI 10.1371/journal.pone.0264129
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Opposing Viewpoints
Gale In Context: Science
ProQuest Central (Corporate)
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Nursing & Allied Health Database
Ecology Abstracts
Entomology Abstracts (Full archive)
Immunology Abstracts
Meteorological & Geoastrophysical Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Agricultural Science Collection
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Advanced Technologies & Aerospace Collection
Agricultural & Environmental Science Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Materials Science Collection
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Materials Science Database
Nursing & Allied Health Database (Alumni Edition)
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest Engineering Collection
ProQuest Biological Science Collection
Agricultural Science Database
ProQuest Health & Medical Collection
Medical Database ProQuest
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Engineering Database
Nursing & Allied Health Premium
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
Environmental Science Database
Materials Science Collection
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
Engineering Collection
Environmental Science Collection
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Agricultural Science Database
Publicly Available Content Database
ProQuest Central Student
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Meteorological & Geoastrophysical Abstracts
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Engineering Collection
Advanced Technologies & Aerospace Collection
Engineering Database
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Agricultural Science Collection
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Environmental Science Collection
Entomology Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
Materials Science Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
ProQuest Engineering Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Agricultural & Environmental Science Collection
AIDS and Cancer Research Abstracts
Materials Science Database
ProQuest Materials Science Collection
ProQuest Public Health
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Animal Behavior Abstracts
Materials Science & Engineering Collection
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef



Agricultural Science Database


MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
Medicine
DocumentTitleAlternate Pioglitazone in diabetic kidney disease
EISSN 1932-6203
ExternalDocumentID 2629808942
oai_doaj_org_article_3f51da4eadbf4fdb927044c44f44f297
PMC8853567
A694065599
35176115
10_1371_journal_pone_0264129
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Taiwan
GeographicLocations_xml – name: Taiwan
GrantInformation_xml – fundername: ;
  grantid: CSH-2022-A-002
GroupedDBID ---
123
29O
2WC
53G
5VS
7RV
7X2
7X7
7XC
88E
8AO
8C1
8CJ
8FE
8FG
8FH
8FI
8FJ
A8Z
AAFWJ
AAUCC
AAWOE
AAYXX
ABDBF
ABIVO
ABJCF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
APEBS
ARAPS
ATCPS
BAWUL
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BKEYQ
BPHCQ
BVXVI
BWKFM
CCPQU
CITATION
CS3
D1I
D1J
D1K
DIK
DU5
E3Z
EAP
EAS
EBD
EMOBN
ESX
EX3
F5P
FPL
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
IAO
IEA
IGS
IHR
IHW
INH
INR
IOV
IPY
ISE
ISR
ITC
K6-
KB.
KQ8
L6V
LK5
LK8
M0K
M1P
M48
M7P
M7R
M7S
M~E
NAPCQ
O5R
O5S
OK1
OVT
P2P
P62
PATMY
PDBOC
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PTHSS
PV9
PYCSY
RNS
RPM
RZL
SV3
TR2
UKHRP
WOQ
WOW
~02
~KM
3V.
ADRAZ
BBORY
CGR
CUY
CVF
ECM
EIF
IPNFZ
NPM
RIG
PMFND
7QG
7QL
7QO
7SN
7SS
7T5
7TG
7TM
7U9
7XB
8FD
8FK
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
KL.
M7N
P64
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
RC3
7X8
5PM
PUEGO
-
02
AAPBV
ABPTK
ADACO
B0M
BBAFP
KM
ID FETCH-LOGICAL-c692t-2a87ffb792a2002b35d368f7604e24a94e0807db48c9d0688f5fa7ef982cfc3c3
IEDL.DBID M48
ISSN 1932-6203
IngestDate Sun Jul 03 03:48:39 EDT 2022
Wed Aug 27 01:32:02 EDT 2025
Thu Aug 21 14:31:46 EDT 2025
Fri Jul 11 05:50:17 EDT 2025
Fri Jul 25 11:20:34 EDT 2025
Tue Jun 17 20:31:54 EDT 2025
Tue Jun 10 20:47:35 EDT 2025
Fri Jun 27 05:09:06 EDT 2025
Fri Jun 27 04:21:54 EDT 2025
Thu May 22 21:22:40 EDT 2025
Wed Feb 19 02:27:07 EST 2025
Tue Jul 01 03:53:44 EDT 2025
Thu Apr 24 22:55:17 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Creative Commons Attribution License
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c692t-2a87ffb792a2002b35d368f7604e24a94e0807db48c9d0688f5fa7ef982cfc3c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Competing Interests: The authors have declared that no competing interests exist.
ORCID 0000-0002-9342-5467
OpenAccessLink https://doaj.org/article/3f51da4eadbf4fdb927044c44f44f297
PMID 35176115
PQID 2629808942
PQPubID 1436336
PageCount e0264129
ParticipantIDs plos_journals_2629808942
doaj_primary_oai_doaj_org_article_3f51da4eadbf4fdb927044c44f44f297
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8853567
proquest_miscellaneous_2630921870
proquest_journals_2629808942
gale_infotracmisc_A694065599
gale_infotracacademiconefile_A694065599
gale_incontextgauss_ISR_A694065599
gale_incontextgauss_IOV_A694065599
gale_healthsolutions_A694065599
pubmed_primary_35176115
crossref_primary_10_1371_journal_pone_0264129
crossref_citationtrail_10_1371_journal_pone_0264129
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-02-17
PublicationDateYYYYMMDD 2022-02-17
PublicationDate_xml – month: 02
  year: 2022
  text: 2022-02-17
  day: 17
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: San Francisco
– name: San Francisco, CA USA
PublicationTitle PloS one
PublicationTitleAlternate PLoS One
PublicationYear 2022
Publisher Public Library of Science
Public Library of Science (PLoS)
Publisher_xml – name: Public Library of Science
– name: Public Library of Science (PLoS)
References S Yaghi (pone.0264129.ref033) 2018; 137
R Bonner (pone.0264129.ref002) 2020; 47
American Diabetes Association (pone.0264129.ref025) 2019; 42
E Mannucci (pone.0264129.ref029) 2008; 10
SE Nissen (pone.0264129.ref030) 2010; 170
GJ Ko (pone.0264129.ref019) 2008; 23
K Isshiki (pone.0264129.ref018) 2000; 49
E Kiss-Tóth (pone.0264129.ref027) 2008; 2008
WN Kernan (pone.0264129.ref032) 2016; 374
YJ Oh (pone.0264129.ref034) 2017; 12
Action to Control Cardiovascular Risk in Diabetes Study Group (pone.0264129.ref003) 2008; 358
Z Wang (pone.0264129.ref014) 2019; 118
E Kornelius (pone.0264129.ref023) 2015; 128
V Perkovic (pone.0264129.ref006) 2019; 380
YH Chang (pone.0264129.ref017) 2017; 54
KR Tuttle (pone.0264129.ref035) 2021; 77
W Wang (pone.0264129.ref021) 2007; 2007
E Kornelius (pone.0264129.ref024) 2020; 26
JA Dormandy (pone.0264129.ref026) 2005; 366
Y Zhou (pone.0264129.ref015) 2020; 105
E Chiquette (pone.0264129.ref031) 2004; 164
R DeFronzo (pone.0264129.ref036) 2016; 18
SP Marso (pone.0264129.ref005) 2016; 375
P Saeedi (pone.0264129.ref001) 2019; 157
GL Bakris (pone.0264129.ref004) 2000; 36
YH Chen (pone.0264129.ref016) 2015; 10
DT Investigators (pone.0264129.ref028) 2006; 368
PA Sarafidis (pone.0264129.ref013) 2010; 55
L Agrawal (pone.0264129.ref011) 2011; 34
T Okada (pone.0264129.ref022) 2006; 55
JC Jha (pone.0264129.ref008) 2016; 25
Y Lu (pone.0264129.ref020) 2013; 8
C Nigro (pone.0264129.ref009) 2019; 8
F Ismail-Beigi (pone.0264129.ref010) 2010; 376
HJ Heerspink (pone.0264129.ref007) 2020; 383
P Corrales (pone.0264129.ref012) 2018; 19
References_xml – volume: 19
  start-page: 2063
  year: 2018
  ident: pone.0264129.ref012
  article-title: Maintenance of kidney metabolic homeostasis by PPAR gamma
  publication-title: International journal of molecular sciences
  doi: 10.3390/ijms19072063
– volume: 18
  start-page: 454
  year: 2016
  ident: pone.0264129.ref036
  article-title: Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor
  publication-title: Diabetes, Obesity and Metabolism
  doi: 10.1111/dom.12652
– volume: 10
  start-page: e0129922
  year: 2015
  ident: pone.0264129.ref016
  article-title: Thiazolidinediones and risk of long-term dialysis in diabetic patients with advanced chronic kidney disease: a nationwide cohort study
  publication-title: PloS one
  doi: 10.1371/journal.pone.0129922
– volume: 128
  start-page: 977
  year: 2015
  ident: pone.0264129.ref023
  article-title: The diabetes shared care program and risks of cardiovascular events in type 2 diabetes
  publication-title: The American Journal of Medicine
  doi: 10.1016/j.amjmed.2015.03.025
– volume: 170
  start-page: 1191
  year: 2010
  ident: pone.0264129.ref030
  article-title: Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality
  publication-title: Archives of internal medicine
  doi: 10.1001/archinternmed.2010.207
– volume: 12
  start-page: e0170874
  year: 2017
  ident: pone.0264129.ref034
  article-title: The impact of renin-angiotensin system blockade on renal outcomes and mortality in pre-dialysis patients with advanced chronic kidney disease
  publication-title: PloS one
  doi: 10.1371/journal.pone.0170874
– volume: 2008
  start-page: 183108
  year: 2008
  ident: pone.0264129.ref027
  article-title: PPARgamma in Kidney Physiology and Pathophysiology
  publication-title: PPAR Res
  doi: 10.1155/2008/183108
– volume: 34
  start-page: 2090
  year: 2011
  ident: pone.0264129.ref011
  article-title: Observation on renal outcomes in the Veterans Affairs Diabetes Trial
  publication-title: Diabetes care
  doi: 10.2337/dc11-0175
– volume: 105
  start-page: 1670
  year: 2020
  ident: pone.0264129.ref015
  article-title: Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis.
  publication-title: The Journal of Clinical Endocrinology & Metabolism
  doi: 10.1210/clinem/dgz252
– volume: 137
  start-page: 455
  year: 2018
  ident: pone.0264129.ref033
  article-title: Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS trial (Insulin Resistance Intervention After Stroke)
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.117.030458
– volume: 8
  start-page: e79815
  year: 2013
  ident: pone.0264129.ref020
  article-title: SUMOylation of PPARγ by rosiglitazone prevents LPS-induced NCoR degradation mediating down regulation of chemokines expression in renal proximal tubular cells
  publication-title: PloS one.
  doi: 10.1371/journal.pone.0079815
– volume: 77
  start-page: 94
  year: 2021
  ident: pone.0264129.ref035
  article-title: SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the National Kidney Foundation
  publication-title: American Journal of Kidney Diseases
  doi: 10.1053/j.ajkd.2020.08.003
– volume: 26
  start-page: 1486
  year: 2020
  ident: pone.0264129.ref024
  article-title: Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease
  publication-title: Endocrine Practice
  doi: 10.4158/EP-2020-0143
– volume: 375
  start-page: 311
  year: 2016
  ident: pone.0264129.ref005
  article-title: Liraglutide and cardiovascular outcomes in type 2 diabetes
  publication-title: New England Journal of Medicine
  doi: 10.1056/NEJMoa1603827
– volume: 2007
  start-page: 62641
  year: 2007
  ident: pone.0264129.ref021
  article-title: Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists attenuate the profibrotic response induced by TGF-β1 in renal interstitial fibroblasts
  publication-title: Mediators of inflammation
  doi: 10.1155/2007/62641
– volume: 42
  start-page: S61
  issue: Suppl 1
  year: 2019
  ident: pone.0264129.ref025
  article-title: Glycemic Targets: Standards of Medical Care in Diabetes-2019
  publication-title: Diabetes Care
  doi: 10.2337/dc19-S006
– volume: 8
  start-page: 749
  year: 2019
  ident: pone.0264129.ref009
  article-title: Dicarbonyl stress at the crossroads of healthy and unhealthy aging
  publication-title: Cells
  doi: 10.3390/cells8070749
– volume: 358
  start-page: 2545
  issue: 24
  year: 2008
  ident: pone.0264129.ref003
  article-title: Effects of intensive glucose lowering in type 2 diabetes
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0802743
– volume: 366
  start-page: 1279
  year: 2005
  ident: pone.0264129.ref026
  article-title: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
  publication-title: The Lancet
  doi: 10.1016/S0140-6736(05)67528-9
– volume: 376
  start-page: 419
  year: 2010
  ident: pone.0264129.ref010
  article-title: Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
  publication-title: The Lancet
  doi: 10.1016/S0140-6736(10)60576-4
– volume: 368
  start-page: 1096
  year: 2006
  ident: pone.0264129.ref028
  article-title: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
  publication-title: The Lancet
  doi: 10.1016/S0140-6736(06)69420-8
– volume: 164
  start-page: 2097
  year: 2004
  ident: pone.0264129.ref031
  article-title: A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
  publication-title: Archives of Internal Medicine
  doi: 10.1001/archinte.164.19.2097
– volume: 380
  start-page: 2295
  year: 2019
  ident: pone.0264129.ref006
  article-title: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
  publication-title: New England Journal of Medicine
  doi: 10.1056/NEJMoa1811744
– volume: 374
  start-page: 1321
  year: 2016
  ident: pone.0264129.ref032
  article-title: Pioglitazone after ischemic stroke or transient ischemic attack
  publication-title: N engl J med
  doi: 10.1056/NEJMoa1506930
– volume: 383
  start-page: 1436
  year: 2020
  ident: pone.0264129.ref007
  article-title: Dapagliflozin in patients with chronic kidney disease
  publication-title: New England Journal of Medicine
  doi: 10.1056/NEJMoa2024816
– volume: 25
  start-page: 657
  year: 2016
  ident: pone.0264129.ref008
  article-title: Diabetes and kidney disease: role of oxidative stress.
  publication-title: Antioxidants & redox signaling
  doi: 10.1089/ars.2016.6664
– volume: 118
  start-page: 109346
  year: 2019
  ident: pone.0264129.ref014
  article-title: Pioglitazone downregulates Twist-1 expression in the kidney and protects renal function of Zucker diabetic fatty rats
  publication-title: Biomedicine & Pharmacotherapy
  doi: 10.1016/j.biopha.2019.109346
– volume: 49
  start-page: 1022
  year: 2000
  ident: pone.0264129.ref018
  article-title: Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats
  publication-title: Diabetes
  doi: 10.2337/diabetes.49.6.1022
– volume: 36
  start-page: 646
  year: 2000
  ident: pone.0264129.ref004
  article-title: Preserving renal function in adults with hypertension and diabetes: a consensus approach
  publication-title: American journal of kidney diseases
  doi: 10.1053/ajkd.2000.16225
– volume: 54
  start-page: 561
  year: 2017
  ident: pone.0264129.ref017
  article-title: Renal function preservation with pioglitazone or with basal insulin as an add-on therapy for patients with type 2 diabetes mellitus
  publication-title: Acta diabetologica
  doi: 10.1007/s00592-017-0983-0
– volume: 55
  start-page: 1666
  year: 2006
  ident: pone.0264129.ref022
  article-title: Thiazolidinediones ameliorate diabetic nephropathy via cell cycle–dependent mechanisms
  publication-title: Diabetes
  doi: 10.2337/db05-1285
– volume: 23
  start-page: 2750
  year: 2008
  ident: pone.0264129.ref019
  article-title: Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats
  publication-title: Nephrology Dialysis Transplantation
  doi: 10.1093/ndt/gfn157
– volume: 157
  start-page: 107843
  year: 2019
  ident: pone.0264129.ref001
  article-title: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas
  publication-title: Diabetes research and clinical practice
  doi: 10.1016/j.diabres.2019.107843
– volume: 10
  start-page: 1221
  year: 2008
  ident: pone.0264129.ref029
  article-title: Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials
  publication-title: Diabetes, Obesity and Metabolism
  doi: 10.1111/j.1463-1326.2008.00892.x
– volume: 47
  start-page: 645
  year: 2020
  ident: pone.0264129.ref002
  article-title: Diabetic Kidney Disease.
  publication-title: Primary Care: Clinics in Office Practice
  doi: 10.1016/j.pop.2020.08.004
– volume: 55
  start-page: 835
  year: 2010
  ident: pone.0264129.ref013
  article-title: Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis
  publication-title: American Journal of Kidney Diseases
  doi: 10.1053/j.ajkd.2009.11.013
SSID ssj0053866
Score 2.4535737
Snippet There is limited information on the efficacy of pioglitazone in diabetic kidney diseases (DKD). We evaluated whether pioglitazone exerts renal-protective...
SourceID plos
doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e0264129
SubjectTerms Aged
Albuminuria - epidemiology
Albuminuria - prevention & control
Biology and Life Sciences
Cardiovascular disease
Care and treatment
Creatinine
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetic nephropathies
Diabetic Nephropathies - etiology
Diabetic Nephropathies - metabolism
Diabetic Nephropathies - pathology
Diabetic Nephropathies - prevention & control
Diabetic nephropathy
Endocrinology
Enrollments
Epidermal growth factor receptors
Female
Glomerular Filtration Rate
Glucose
Hemodialysis
Hospitals
Humans
Hypertension
Hypoglycemic Agents - therapeutic use
Internal medicine
Kidney - drug effects
Kidney - pathology
Kidney diseases
Kidney transplantation
Kidneys
Male
Medicine
Medicine and Health Sciences
Metabolism
Middle Aged
Patients
Pioglitazone
Pioglitazone - therapeutic use
Retrospective Studies
Taiwan - epidemiology
Transplantation
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQnrggyquBAgYhAYe0ie3Y8bEgqoJ4SEBRb1H8aiOqZNXsHsqvZybxhgZVKgeknOJJ5Mwj_iaZ-UzIC1PmmfUiT7m1GhKU3KUlrFNpUbvAMuOYMPgd8tNneXgkPhwXx5e2-sKasJEeeFTcHg9F7moBD2yCCM5opjIhrBABDqaHPnJY8zbJ1PgOhiiWMjbKcZXvRbvsLrvW70LWIfIBUv5ZiAa-_umtvFiedf1VkPPvyslLS9HBbXIrYki6P859i9zw7R2yFaO0p68ilfTru-QjeAH1yBJR2wvaBbpsuhOk5f4FU6SAV-m5x1tFtgawEW1aOn6PbSz92bjWX9D4E-ceOTp49_3tYRr3T0it1GyVsrpUIRilWY2lGIYXjssyKJkJz0SthQe4qJwRpdUON58JRaiVD7pkNlhu-X2yaGE624RmQlmnILgDQA5rahO4cTIogF_WBa0TwjfKrGwkF8c9Ls6q4Y-ZgiRj1E2FJqiiCRKSTlctR3KNa-TfoJ0mWaTGHk6Aw1TRYarrHCYhT9HK1dhnOgV4tS81gBskYEvI80EC6TFarL85qdd9X73_8uMfhL59nQm9jEKhA3WArceeB3gmpN2aSe7MJCHI7Wx4G31yo5W-YpLpMiu1YHDlxk-vHn42DeNNsaau9d0aZXimAeGpLCEPRreeNMuLXElIFhKiZg4_U_18pG1OB3byEgBgIdXD_2GrR-Qmw3YT3IBH7ZDF6nztHwMIXJknQ7z_BqnUXDU
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZgkRAXRMujgQIGIQGHtInj2PEJFURVEAUJKNpbFL-2K6pk2eweyq9nJvGmBFWAtKf1JHJmPPY39vgbQp7pIk2M42mcGaMgQEltXMA6FeeV9SzRlnGN-5DHH8XRCX8_zadhw60NaZWbObGbqG1jcI98nwmmiqRQnL1a_IixahSeroYSGlfJNaQuw5QuOR0CLvBlIcJ1uUym-8E6e4umdnsQe_C0A5YXy1HH2j_MzZPFWdNeBjz_zJ_8bUE6vEVuBiRJD3rTb5Errt4m14_DWfk22Qpu29IXgVv65W3yAYYFdUgbUZlz2ni6mDcz5On-Cb2lAGDp0uFbA30DGI3Oa9pv0M4N_T63tTun4VTnDjk5fPv1zVEcCirERii2illVSO-1VKzC3Ayd5TYThZci4Y7xSnEH-FFazQujLFaj8bmvpPOqYMabzGR3yaSG7uwQmnBprARv94BBjK60z7QVXgIeM9YrFZFso9fSBLZxLHpxVnZHaBKijl5NJVqjDNaISDw8tejZNv4h_xpNNsgiV3b3R7OclcH1ysznqa04uIz23FutmEw4N5x7-DElI_IYDV72F08Hjy8PhAK0g4xsEXnaSSBfRo0JObNq3bblu0_f_kPoy-eR0PMg5BtQB9i6vwQB34Q8XCPJ3ZEkeL0ZNe_g8NxopS0v_AOe3AzZy5ufDM34Ukyyq12zRpksUQD5ZBKRe_0IHzSb5akUED1ERI7G_kj145Z6ftrRlReACHMh7_-9Ww_IDYY3S7DWjtwlk9Vy7R4C3lvpR51T_wKPPFYj
  priority: 102
  providerName: ProQuest
Title The efficacy of pioglitazone for renal protection in diabetic kidney disease
URI https://www.ncbi.nlm.nih.gov/pubmed/35176115
https://www.proquest.com/docview/2629808942
https://www.proquest.com/docview/2630921870
https://pubmed.ncbi.nlm.nih.gov/PMC8853567
https://doaj.org/article/3f51da4eadbf4fdb927044c44f44f297
http://dx.doi.org/10.1371/journal.pone.0264129
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLa27oUXxLgtYxSDkICHVInjxPEDQtu0MhAbaFC0tyi241JRJaUXifLrOSdxI4LKRaryUB9bybnYn2_fIeSpSsNAFzz0I60lTFBC46cwTvlxbiwLlGFc4TrkxWVyPuJvr-PrHbLJ2eoUuNg6tcN8UqP5dPD92_oVBPzLOmuDCDeVBrOqLAYwp-Awhu2SPRibBIbqBW_3FSC6691LRC1-woLIXab7Uyudwarm9G977t5sWi22wdLfT1f-MlwNb5GbDmfS48Yx9slOUd4m-y6SF_S5o5t-cYe8A0-hBTJJ5HpNK0tnk2qM1N0_4BUpYFo6L7Apx-gAdqSTkjZrthNNv05MWayp2-i5S0bDs0-n577LseDrRLKlz_JUWKuEZDke11BRbKIktSIJeMF4LnkBkFIYxVMtDSaosbHNRWFlyrTVkY7ukV4Jr3NAaMCFNgI6AAuwRKtc2UiZxAqAaNpYKT0SbZSZaUdAjnkwplm9qyZgItLoJkMTZM4EHvHbWrOGgOMf8idop1YW6bPrP6r5OHPRmEU2Dk3OIYqU5dYoyUTAuebcwo9J4ZFHaOWsuYvadgLZcSIBACFJm0ee1BJIoVHiGZ1xvlossjfvP_-H0MerjtAzJ2QrUAfYurkXAd-E1FwdyaOOJHQEulN8gD650coiYwmTaZBKzqDmxk-3Fz9ui7FRPHdXFtUKZaJAAgoUgUfuN27dajaKQ5HAhMIjouPwHdV3S8rJl5rBPAWQGCfi8O8f9IDcYHjZBNPviCPSW85XxUOAgEvVJ7viWsAzPQ3xOXzdJ3snZ5cfrvr1okq_jvqfxA9fbg
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGkYAXxMbHAoMZBAIesiWOE8cPCI2PqWXtkGBDfQuJHZeKKSlrK1T-KP5G7hInI2gCXib1qb5Yyd35_Dt__I6Qx1nseyrnvhsoJSFB8bUbwzzlhqk2zMs04xmuQ44Oo_4xfzcOx2vkZ3MXBo9VNjGxCtS6VLhGvssiJmMvlpy9nH1zsWoU7q42JTRqtzjIV98hZZu_GLwB-z5hbP_t0eu-a6sKuCqSbOGyNBbGZEKyFA8oZEGogyg2IvJ4zngqeQ4gSuiMx0pqLMliQpOK3MiYKaMCFUC_l8hl-CAPR5QYtwkexI4ostfzAuHvWm_YmZVFvgO5DvcrIHs2_VVVAtq5oDc7KefnAd0_z2v-NgHu3yDXLXKle7WrrZO1vNggV0Z2b36DrNswMafPLJf185tkCG5Ic6SpSNWKlobOpuUEecF_wNtSAMz0NMdeLV0EOAmdFrReEJ4q-nWqi3xF7S7SLXJ8Iaq-TXoFvM4moR4XSguILgYwj8rSzASZjowA_Ke0kdIhQaPXRFl2cyyycZJUW3YCspxaTQlaI7HWcIjbPjWr2T3-If8KTdbKIjd39Ud5OknsUE8CE_o65TBEM8ONziQTHueKcwM_JoVDttHgSX3RtY0wyV4kAV0hA5xDHlUSyM9R4AGgSbqcz5PB-0__IfTxQ0foqRUyJagDbF1fuoBvQt6vjuRWRxKijOo0b6J7NlqZJ2fjEZ5sXPb85odtM3aKh_qKvFyiTOBJgJjCc8id2sNbzQahLyLIVhwiOr7fUX23pZh-qejRY0CgYSTu_v21tsnV_tFomAwHhwf3yDWGt1qwzo_YIr3F6TK_D1hzkT2oBjglny86ovwCLDiS-A
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKIlVcEC2PBgo1CAQc0k0cJ44PCBXKqqUPELRobyGx42VFlSz7EFp-Gr-OmcRJCaqAS6Wc4onlzMvf-DFDyOMs9j2Vc98NlJIQoPjajWGecsNUG-ZlmvEM1yGPjqO9U_52GA5XyM_mLgweq2x8YuWodalwjbzPIiZjL5ac9Y09FvF-d_By8s3FClK409qU06hV5CBffofwbfZifxdk_YSxwZuT13uurTDgqkiyucvSWBiTCclSPKyQBaEOotiIyOM546nkOQAqoTMeK6mxPIsJTSpyI2OmjApUAP1eIVdFEPpoY2LYBnvgR6LIXtULhN-3mrE9KYt8G-Ie7leg9nwqrCoGtPNCb3JWzi4CvX-e3fxtMhzcINctiqU7tdqtkZW8WCerR3affp2sWZcxo89sXuvnN8khqCTNMWVFqpa0NHQyLkeYI_wHjJYCeKbTHHu1qSNAYei4oPXi8FjRr2Nd5Etqd5RukdNLYfVt0itgOBuEelwoLcDTGMA_KkszE2Q6MgKwoNJGSocEDV8TZTOdY8GNs6TavhMQ8dRsSlAaiZWGQ9z2q0md6eMf9K9QZC0t5umuXpTTUWLNPglM6OuUg7lmhhudSSY8zhXnBh4mhUO2UOBJfem19TbJTiQBaWE2OIc8qigwV0eBWj9KF7NZsv_u038QffzQIXpqiUwJ7ABZ1xcw4J8wB1iHcrNDCR5HdZo3UD0brsySc9uELxuVvbj5YduMneIBvyIvF0gTeBLgpvAccqfW8JazYF0igsjFIaKj-x3Wd1uK8ZcqVXoMaDSMxN2_D2uLrIIvSQ73jw_ukWsML7hgyR-xSXrz6SK_D7Bznj2o7JuSz5ftUH4BBtGXLg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+efficacy+of+pioglitazone+for+renal+protection+in+diabetic+kidney+disease&rft.jtitle=PloS+one&rft.au=Ho%2C+Chao-Chung&rft.au=Yang%2C+Yi-Sun&rft.au=Huang%2C+Chien-Ning&rft.au=Lo%2C+Shih-Chang&rft.date=2022-02-17&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=17&rft.issue=2&rft.spage=e0264129&rft_id=info:doi/10.1371%2Fjournal.pone.0264129&rft.externalDocID=A694065599
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon